Tag - IRLAB-A

IRLAB Therapeutics (STO:IRLAB-A; FRA:6IRA) has announced that it has enrolled the last patient in its ongoing Phase IIb study of Pirepemat for Parkingson’s disease. The company also reports that a reduction in falls has...